Blog
RSS FeedPosted by Michael Wonder on 15 Dec 2023
Biologic patent thickets and terminal disclaimers
14 December 2023 - Spending on biologics in 2021 represented $260 billion or 46% of all spending on prescription drugs in ...
Posted by Michael Wonder on 14 Nov 2023
Inequitable conduct and invalidation of patents related to FDA regulated products
13 November 2023 - Median brand name drug launch prices increased from $2,115 in 2008 to $180,007 in 2021. ...
Posted by Michael Wonder on 14 Nov 2023
Ancillary product patents to extend biologic patent life
13 November 2023 - In 2021, 46% ($260 billion) of all gross prescription drug spending in the US was on biologic ...
Posted by Michael Wonder on 04 Oct 2023
US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic
2 October 2023 - A US Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo ...
Posted by Michael Wonder on 02 Aug 2023
Changes in the number of continuation patents on drugs approved by the FDA
1 August 2023 - Brand name pharmaceutical manufacturers often sustain high prices in the US by obtaining patents that delay generic ...
Posted by Michael Wonder on 29 Jan 2023
How a drug company made $114 billion by gaming the US patent system
28 January 2023 - AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. ...
Posted by Michael Wonder on 26 Jan 2023
Patent reform and lower drug prices should be bipartisan priorities
25 January 2023 - As the 118th Congress convenes this month in Washington D.C., many pundits and advocates have little ...
Posted by Michael Wonder on 13 Jan 2023
Recent patent reform bills and their implications for prescription drugs
13 January 2022 - In 2022, several bills were introduced in Congress to revamp US intellectual property law. ...
Posted by Michael Wonder on 07 Dec 2022
US backs delay to decision on COVID patent waiver extension
6 December 2022 - The United States on Tuesday urged delaying a decision on whether to waive patent protection for ...
Posted by Michael Wonder on 07 Nov 2022
US Supreme Court to hear Amgen bid to revive cholesterol drug patents
4 November 2022 - The US Supreme Court on Friday agreed to hear Amgen's bid to revive patents on its ...
Posted by Michael Wonder on 03 Aug 2022
AbbVie wins appeal in antitrust case over Humira 'patent thicket'
3 August 2022 - A U.S. appeals court on Monday affirmed that AbbVie Inc did not unlawfully block competition by ...
Posted by Michael Wonder on 02 Aug 2022
Characteristics of key patents covering recent FDA approved drugs
1 August 2022 - New drugs are protected by patents that block generic competition and allow manufacturers to charge high prices. ...
Posted by Michael Wonder on 09 Jun 2022
U.S. Senators ask regulators to clear drug patent 'thickets'
9 June 2022 - Letter asks U.S. Patent and Trademark Office to crack down on "highly similar" patents for single ...
Posted by Michael Wonder on 17 May 2022
Understanding ‘evergreening’: making minor modifications of existing medications to extend protections
17 May 2022 - Recent studies have examined strategic behaviours in the pharmaceutical industry that extend patent and regulatory protection, known ...
Posted by Michael Wonder on 25 Feb 2022
Updating the Bayh-Dole Act; march-in rights and transparency
24 February 2022 - The Patent and Trademark Law Amendments Act (Bayh-Dole Act [35 USC §200-212]) was enacted in 1980 and ...